Omeros (OMER) news
Recent news
Omeros Corp - CMS grants NTAP status for Yartemlea under FY2027 IPPS final rule
Omeros Corporation (NASDAQ: OMER) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA® (J1289), effective July 1, 2026. This development follows the inclusion of YARTEMLEA in the…
AInvest Wire · Aug 3, 2026Omeros Corp - eligible hospitals to receive additional Medicare reimbursement for Yartemlea from October 1, 2026
AInvest Wire · Aug 3, 2026EMA: Upon receipt of grounds of Omeros Ireland's request, will re-examine opinion on Yartemlea & issue final recommendation
The European Medicines Agency (EMA) has announced that it will re-examine its opinion on Yartemlea following a request submitted by Omeros Ireland Limited, the company behind the drug. The initial opinion, issued on June 25, 2026, recommended the refusal of marketing authorization for Yartemlea, a…
AInvest Wire · Jul 15, 2026Omeros Corp - to request re-examination of CHMP opinion and review by ad hoc expert group
AInvest Wire · Jun 26, 2026Omeros Corp - CHMP adopts negative opinion on Narsoplimab MAA for TA-TMA
AInvest Wire · Jun 26, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.